What do you get when you undertake a cost-benefit analysis of new therapies when prices have yet to be established… Read more »
Tag: Aimmune
Longer Trial Increased Level of Tolerance to AR101 Peanut Therapy
By extending the peanut biologic oral immunotherapy known as AR101 by 28 weeks, a new study finds that a majority… Read more »
Aimmune Applies to Move Forward on Testing Novel Egg Allergy Treatment
Aimmune Therapeutics, the company behind the AR101 oral immunotherapy (OIT) treatment for peanut allergy, announced on Dec. 20, 2018 that… Read more »
NEJM Publishes Positive Study Data on OIT Biologic for Peanut Allergy
The positive results of a pivotal Phase 3 study of a peanut biologic oral immunotherapy known as AR101 were published… Read more »
Allergists Excited for Peanut Therapy That’s in Line for Approval
Hundreds of allergists turned out to see Dr. Stacie Jones present highly anticipated study results at the AAAAI/WAO joint congress… Read more »
FDA Labels Peanut OIT Treatment “Breakthrough Therapy”
All of the participants in the Phase II trial were able to tolerate nearly 2 peanut kernels at the end of two months.